Mafu a Autoimmune, a mefuta e fapaneng mme hangata e le mafu a hanyetsanang le a tebileng, ke e 'ngoe ea litataiso tsa bohlokoa tsa nts'etsopele ea hona joale ea lithethefatsi.JAK-STAT ke e 'ngoe ea litsela tse seng kae tsa immunomodulatory tse netefalitsoeng, haholo-holo JAK inhibitors.Lithethefatsi tse ngata,joalo ka tofacitinib, li rekisitsoe lefatšeng ka bophara.

Sepheo sa JAK se entsoe ka nako e ka tlase ho lilemo tse 20, empa hajoale mefuta e ka bang 7 e amohetsoe hore e bapatsoe.Lipontšo ke haholo-holo lihlahala le mafu a ho itšireletsa mafung, 'me matšoao a hloekisitsoeng haholo ke masapo a masapo le ramatiki ea ramatiki.Lintlha tse latelang li lebisa tlhokomelo ho JAK inhibitor ea pele (tofacitinib) bakeng sa phekolo ea ramatiki ea lefuba.

Tofacitinib ke molek'hule e nyane ea molomo ea JAK inhibitor e ntlafalitsoeng ke Pfizer.E na le khetho e ntle ea JAK.Ka November 2012, US FDA e amohetse tofacitinib citrate bakeng sa phekolo ea methotrexate e sa lekaneng kapa e sa mamelle karabo ea phekolo.Sehlahisoa sena ke inhibitor ea pele ea JAK e amohetsoeng ke FDA bakeng sa kalafo ea ramatiki ea ramatiki.Hona joale, ntle le matšoao a amohelehang, tofacitinib e ntse e lekoa bakeng sa katleho ea eona ho ankylosing spondylitis, atopic dermatitis, keratoconjunctivitis sicca le lefu la Crohn.Mabapi le thekiso ea lefats'e, thekiso ea selemo le selemo ea tofacitinib ka 2017 e ne e feta $ 1 billion, mme thekiso ea selemo le selemo ka 2019 e fihlile ho US $ 2.242 billion.

Litsela tse fapaneng tsa maiketsetso li tla ba le tšusumetso e kholo ho chai le boleng ba li-API.Tlhahiso ea rona ea tofacitinib citrate e qoba tsela e nang le tokelo ea molao.Tsela ea maiketsetso e hloka litšenyehelo tse tlase tsa thepa e tala, chai e ngata, litšila tse le 'ngoe le bohloeki li ka laoloa ka har'a mefuta e sa tšoaneng, kapa e ka etsoa ke bareki.Kahoo etsa hore re be le molemo o totobetseng 'marakeng.Hajoale matla a rona e ka ba 50kg ka khoeli, 'me tofacitinib citrate e seng e rometsoe USA, Mexico, Franch, Bangladesh, joalo-joalo.